

PRESS RELEASE

15 October 2021 09:05:00 CEST

Senzime reports TetraGraph highlights from the American Society of Anesthesiologists Annual Meeting

NEWS: Uppsala October 15, 2021. Senzime is proud to announce that the TetraGraph system received great focus during the American Society of Anesthesiology's Annual meeting in San Diego October 8-12, as presented in the highlights below. A study done with the TetraGraph was selected Editors' choice in Anesthesiology and TetraGraph was featured in four different poster presentations at the meeting with two focusing on pediatric use, one using different muscle groups and one a prospective trial in restricted arm movement surgical settings.

The Annual meeting is an opportunity for the industry to meet with key opinion leaders to discuss the need and usability of our innovations and we are so happy that we were able to meet in person this year.

The Senzime team as well as the Mercury team demonstrated the TetraGraph in their respective booths, generating a great network of contacts with anesthesiologists to be followed by meetings in the near future.

As previously communicated the TetraGraph was featured on the front cover of the October 2021 edition of Anesthesiology, the Official Journal of the American Society of Anesthesiology distributed also at the meeting [Link to journal here](#).

Each month the editors of Anesthesiology select one paper to be highlighted with a video abstract, for the month of October they selected the paper featuring TetraGraph; *Ipsilateral and Simultaneous Comparison of Responses from Acceleromyography- and Electromyography-based Neuromuscular Monitors* by Nemes et al.

You can [watch the video](#) here.

The need for neuromuscular monitoring when blocking agents are administered was discussed in a wide range of settings and the TetraGraph system was mentioned and shown in most of them. [Use this link](#) if you wish to see pictures from the meeting.

- Dr. Renew, *What you see is what you get. Or is it? Updates on Objective monitoring*
- Dr. Lien et al, *Quantitative Neuromuscular Monitoring: More Important and More Feasible Than You May Think*
- Dr Caldwell et al, *Neuromuscular Blockade in the Ambulatory Setting: Safe Practices*
- Dr Kwaku Owusu-Bediako presented two posters using TetraGraph at Nationwide Children's Hospital
 - Feasibility of pediatric neuromuscular monitoring in laparoscopic (restricted arm movement) surgical settings
 - Quantitative train-of-four monitoring in pediatric patients using electromyography
- Dr Vivian Hernandez presented two posters using TetraGraph at Mayo Clinic, FL

- Comparison of Adductor Pollicis and Flexor Hallucis Brevis Muscles (Thumb vs. Great Toe) as Sites for Neuromuscular Monitoring with Electromyography after Sugammadex Antagonism
- Electromyographic and acceleromyographic monitoring in restricted arm movement surgical setting. A prospective, randomized trial

"After all our meetings and talks with a great number of anesthesiologists, it is encouraging to learn that quantitative monitoring is a top priority topic around the globe. So proud of the Senszime team in our continued efforts to Prevent the Preventable, says Pia Renaudin, CEO Senszime ", says Pia Renaudin, CEO Senszime.

ABOUT EMG

EMG involves stimulation of a peripheral nerve and measurement of the response generated by the contraction of the innervated muscle. The difference compared to other techniques is that EMG measures an electrical event that occurs in the neuromuscular connection. As the measurement is not dependent on a physical movement (required by other technologies in the field such as AMG and KMG), EMG is a better indicator of pure neuromuscular function. Anesthesia experts worldwide believe that EMG is the new gold standard in NMT monitoring.

For further information, please contact:

Pia Renaudin, CEO of Senszime AB

Phone: +46 (0) 70-813 34 17, email: pia.renaudin@senzime.com

About Senszime

Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senszime operates in growing markets that in Europe and the United States are valued in excess of SEK 15 billion. The company's shares are listed on Nasdaq Stockholm's main market (ticker SEZI) since June, 30 2021. www.senzime.com

Attachments

[Senzime reports TetraGraph highlights from the American Society of Anesthesiologists Annual Meeting](#)